Presentation is loading. Please wait.

Presentation is loading. Please wait.

by Alex C. Spyropoulos, and James D. Douketis

Similar presentations


Presentation on theme: "by Alex C. Spyropoulos, and James D. Douketis"— Presentation transcript:

1 by Alex C. Spyropoulos, and James D. Douketis
How I treat anticoagulated patients undergoing an elective procedure or surgery by Alex C. Spyropoulos, and James D. Douketis Blood Volume 120(15): October 11, 2012 ©2012 by American Society of Hematology

2 Suggested periprocedural heparin bridging strategies for patients on chronic VKA based on patient thromboembolic and procedural bleed risk. Suggested periprocedural heparin bridging strategies for patients on chronic VKA based on patient thromboembolic and procedural bleed risk. Data from the 9th edition ACCP Guidelines: all grade 2C, except intermediate TE risk.7 *For high-bleed risk procedures: wait a full hours before reinitiating postprocedural heparin (LMWH) bridging (especially treatment dose); stepwise increase in postprocedural heparin (LMWH) dose from prophylactic dose first hours to intermediate/treatment dose; no postprocedural heparin (LMWH) bridging in very high bleed risk procedures (ie, major neurosurgical or cardiovascular surgeries) but use of mechanical prophylaxis. **Based on individual patient- and procedural-related risk factors for thrombosis and bleeding. Alex C. Spyropoulos, and James D. Douketis Blood 2012;120: ©2012 by American Society of Hematology


Download ppt "by Alex C. Spyropoulos, and James D. Douketis"

Similar presentations


Ads by Google